STOCK TITAN

Protara Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company focused on innovative therapies for cancer and rare diseases, announced its participation in two upcoming investor conferences. These include the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 am ET in Boston, and the Oppenheimer 33rd Annual Healthcare Conference virtually on March 14, 2023, at 1:20 pm ET. Investors can access live webcasts of these events on the Company's website, with recordings available afterward. Protara's lead product, TARA-002, targets non-muscle invasive bladder cancer and lymphatic malformations.

Positive
  • None.
Negative
  • None.

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

  • Cowen 43rd Annual Health Care Conference. A fireside chat will take place on Wednesday, March 8, 2023 at 9:50 am ET in Boston, MA.
  • Oppenheimer 33rd Annual Healthcare Conference. A corporate presentation will take place virtually on Tuesday, March 14, 2023 at 1:20 pm ET.

A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836


FAQ

What upcoming conferences will Protara Therapeutics (TARA) participate in?

Protara Therapeutics will participate in the Cowen 43rd Annual Health Care Conference on March 8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

When is Protara's fireside chat scheduled?

The fireside chat at the Cowen 43rd Annual Health Care Conference is scheduled for March 8, 2023, at 9:50 am ET.

How can I access Protara Therapeutics' conference webcasts?

Webcasts of Protara Therapeutics' events can be accessed through the Events and Presentations section of their website.

What is TARA-002 developed by Protara Therapeutics?

TARA-002 is an investigational cell-based therapy targeting non-muscle invasive bladder cancer and lymphatic malformations.

What date is the virtual presentation by Protara Therapeutics?

The virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, at 1:20 pm ET.

Protara Therapeutics, Inc.

NASDAQ:TARA

TARA Rankings

TARA Latest News

TARA Stock Data

175.89M
33.06M
6.13%
51.11%
13.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK